{"drugs":["Biaxin","Biaxin Filmtab","Biaxin XL","Clarithromycin"],"mono":{"0":{"id":"126900-s-0","title":"Generic Names","mono":"Clarithromycin"},"1":{"id":"126900-s-1","title":"Dosing and Indications","sub":[{"id":"126900-s-1-4","title":"Adult Dosing","mono":"<ul><li>safety and efficacy of extended-release formulations of clarithromycin for treating other infections for which clarithromycin immediate-release are approved have not been established<\/li><li><b>Acute infective exacerbation of chronic bronchitis:<\/b> immediate release, 250 to 500 mg ORALLY twice daily for 7 to 14 days<\/li><li><b>Acute infective exacerbation of chronic bronchitis:<\/b> extended-release tablets, 1000 mg ORALLY once daily for 7 days<\/li><li><b>Bacterial endocarditis; Prophylaxis:<\/b> (high-risk patients; dental, respiratory, or infected skin\/skin structure or musculoskeletal tissue procedures) 500 mg ORALLY 30 to 60 minutes prior to procedure<\/li><li><b>Bartonellosis - HIV infection:<\/b> (bacillary angiomatosis, peliosis hepatis, bacteremia, osteomyelitis) 500 mg ORALLY twice daily for at least 3 months<\/li><li><b>Community acquired pneumonia:<\/b> immediate release, 250 mg ORALLY twice daily for 7 to 14 days<\/li><li><b>Community acquired pneumonia:<\/b> extended-release tablets, 1000 mg ORALLY once daily for 7 days<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group:<\/b> HIV Infection (immediate-release): 500 mg ORALLY twice daily in combination with ethambutol 15 mg\/kg ORALLY daily, with or without rifabutin 300 mg ORALLY daily (guideline dosing)<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group:<\/b> immediate-release: 500 mg ORALLY twice daily (manufacturer dosing)<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group; Prophylaxis - HIV infection:<\/b> (immediate-release, primary prevention) 500 mg ORALLY twice daily<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group; Prophylaxis - HIV infection:<\/b> (immediate-release, secondary prevention) 500 mg ORALLY twice daily in combination with ethambutol 15 mg\/kg ORALLY daily, with or without rifabutin 300 mg ORALLY daily (guideline dosing)<\/li><li><b>Duodenal ulcer disease - Helicobacter pylori gastrointestinal tract infection:<\/b> (immediate-release, triple therapy) clarithromycin 500 mg, lansoprazole 30 mg, and amoxicillin 1 g ORALLY twice daily for 10 to 14 days; other standard-dose proton pump inhibitors are acceptable in combination with amoxicillin and clarithromycin<\/li><li><b>Duodenal ulcer disease - Helicobacter pylori gastrointestinal tract infection:<\/b> (immediate-release, triple therapy) clarithromycin 500 mg, omeprazole 20 mg, and amoxicillin 1 g ORALLY twice daily for 10 days (an additional 18 days of omeprazole 20 mg once daily when ulcer present at time of initiation of therapy); other standard-dose proton pump inhibitors are acceptable in combination with amoxicillin and clarithromycin<\/li><li><b>Duodenal ulcer disease - Helicobacter pylori gastrointestinal tract infection:<\/b> (immediate-release, triple therapy) clarithromycin 500 mg, metronidazole 500 mg, and a standard dose proton pump inhibitor ORALLY twice daily for 10 to 14 days<\/li><li><b>Duodenal ulcer disease - Helicobacter pylori gastrointestinal tract infection:<\/b> (immediate-release, dual therapy) clarithromycin 500 mg ORALLY 3 times daily (every 8 hours) and omeprazole 40 mg ORALLY once daily in the morning for 14 days (an additional 14 days of omeprazole 20 mg once daily for ulcer healing and symptom relief)<\/li><li><b>Duodenal ulcer disease - Helicobacter pylori gastrointestinal tract infection:<\/b> (immediate-release, dual therapy) CrCl greater than 25 mL\/min: clarithromycin 500 mg ORALLY 2 or 3 times daily and ranitidine bismuth citrate 400 mg ORALLY twice daily for 14 days (an additional 14 days ranitidine bismuth citrate 400 mg twice daily for ulcer healing and symptom relief)<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue, Uncomplicated:<\/b> (immediate-release) 250 mg ORALLY twice daily for 7 to 14 days<\/li><li><b>Lyme disease:<\/b> (alternative to first-line) 500 mg ORALLY twice daily for 14 to 21 days for early localized or early disseminated Lyme disease associated with erythema migrans, or borrelial lymphocytoma<\/li><li><b>Maxillary sinusitis, acute:<\/b> immediate-release, 500 mg ORALLY twice daily for 14 days<\/li><li><b>Maxillary sinusitis, acute:<\/b> extended-release, 1000 mg ORALLY once daily for 14 days<\/li><li><b>Mycobacterium avium complex infection, Lung disease:<\/b> (nodular\/bronchiectatic disease, immediate-release) initial, 1000 mg ORALLY 3 times weekly in combination with ethambutol 25 mg\/kg three times weekly and rifampin 600 mg three times weekly<\/li><li><b>Mycobacterium avium complex infection, Lung disease:<\/b> (cavitary disease, immediate-release) initial, 1000 mg ORALLY daily (or 500 mg twice daily) in combination with ethambutol 15 mg\/kg daily and rifampin 10 mg\/kg daily (MAX 600 mg daily); consider addition of streptomycin OR amikacin<\/li><li><b>Mycobacterium avium complex infection, Lung disease:<\/b> (severe or previously treated disease, immediate-release) initial, 1000 mg ORALLY daily (or 500 mg twice daily) in combination with ethambutol 15 mg\/kg daily, rifabutin 150 to 300 mg daily OR rifampin 10 mg\/kg daily (MAX 600 mg daily); plus streptomycin OR amikacin<\/li><li><b>Pertussis:<\/b> 1 g\/day ORALLY in 2 divided doses for 7 days (guideline dosing)<\/li><li><b>Streptococcal pharyngitis:<\/b> immediate-release, 250 mg ORALLY twice daily for 10 days<\/li><\/ul>"},{"id":"126900-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Acute otitis media:<\/b> (6 months or older) 15 mg\/kg\/day ORALLY (immediate-release) divided every 12 hours for 10 days<\/li><li><b>Bacterial endocarditis; Prophylaxis:<\/b> (high-risk patients; dental, respiratory, or infected skin\/skin structure or musculoskeletal tissue procedures) 15 mg\/kg ORALLY 30 to 60 minutes prior to procedure<\/li><li><b>Bartonellosis - HIV infection:<\/b> (cutaneous bacillary angiomatosis) 15 mg\/kg\/day (MAX 1 g\/day) ORALLY divided into 2 doses\/day for 3 months<\/li><li><b>Community acquired pneumonia:<\/b> (6 months or older, immediate-release) 15 mg\/kg\/day ORALLY (divided every 12 hours) for 10 days (manufacturer recommended dosing)<\/li><li><b>Community acquired pneumonia:<\/b> (older than 3 months) 15 mg\/kg\/day ORALLY in 2 divided doses for 7 to 14 days; maximum dose, 1 g\/day (guideline dosing)<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group:<\/b> HIV Infection (immediate-release): 7.5 to 15 mg\/kg ORALLY twice daily (MAX 500 mg twice daily) in combination with ethambutol 15 to 25 mg\/kg ORALLY daily (MAX 2.5 g\/day); for severe disease, add rifabutin 10 to 20 mg\/kg ORALLY once daily (MAX 300 mg\/day) (guideline dosing)<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group:<\/b> (20 months or older) immediate-release: 7.5 mg\/kg ORALLY twice daily (up to 500 mg twice daily) in combination with other antimycobacterial drugs (manufacturer dosing)<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group; Prophylaxis - HIV infection:<\/b> (immediate-release, primary prevention) 7.5 mg\/kg ORALLY twice daily (MAX 500 mg twice daily)<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group; Prophylaxis - HIV infection:<\/b> (immediate-release, secondary prevention) 7.5 mg\/kg ORALLY twice daily (MAX 500 mg twice daily) in combination with ethambutol 15 to 25 mg\/kg ORALLY daily (MAX 2.5 g\/day), with or without rifabutin 5 mg\/kg ORALLY daily (MAX 300 mg\/day) (guideline dosing)<\/li><li><b>Duodenal ulcer disease - Helicobacter pylori gastrointestinal tract infection:<\/b> (immediate-release, age range 3.3 to 18 years) sequential therapy of omeprazole 1 mg\/kg\/day plus amoxicillin 50 mg\/kg\/day for 5 days, followed by omeprazole 1 mg\/kg\/day, plus clarithromycin 15 mg\/kg\/day, and tinidazole 20 mg\/kg\/day for 5 more days<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue, Uncomplicated:<\/b> (6 months or older; immediate-release) 15 mg\/kg\/day (divided every 12 hours) for 10 days<\/li><li><b>Lyme disease:<\/b> (alternative to first-line) 7.5 mg\/kg ORALLY twice daily for 14 to 21 days for early localized or early disseminated Lyme disease associated with erythema migrans, or borrelial lymphocytoma; maximum daily dose, 1000 mg<\/li><li><b>Maxillary sinusitis, acute:<\/b> (6 months or older, immediate-release) 15 mg\/kg\/day divided every 12 hours for 10 days<\/li><li><b>Mycobacterium avium complex infection, Lung disease:<\/b> (20 months or older, immediate-release) 7.5 mg\/kg ORALLY twice daily (up to 500 mg twice daily) in combination with other antimycobacterial medications<\/li><li><b>Pertussis:<\/b> (1 month or older) 15 mg\/kg\/day ORALLY in 2 divided doses for 7 days; MAX 1 g\/day (guideline dosing)<\/li><li><b>Streptococcal pharyngitis:<\/b> (6 months or older, immediate-release) 15 mg\/kg\/day (divided every 12hours) ORALLY for 10 days<\/li><\/ul>"},{"id":"126900-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>severe renal impairment:<\/b> CrCl less than 30 mL\/min, dose should be reduced 50%<\/li><li><b>hepatic impairment:<\/b> if renal function normal, dose adjustment not necessary<\/li><li><b>geriatric:<\/b> normal renal function, dose adjustment not necessary; consider with severe renal impairment<\/li><\/ul>"},{"id":"126900-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acute infective exacerbation of chronic bronchitis<\/li><li>Acute otitis media<\/li><li>Community acquired pneumonia<\/li><li>Disseminated infection due to Mycobacterium avium-intracellulare group<\/li><li>Disseminated infection due to Mycobacterium avium-intracellulare group; Prophylaxis - HIV infection<\/li><li>Duodenal ulcer disease - Helicobacter pylori gastrointestinal tract infection<\/li><li>Infection of skin AND\/OR subcutaneous tissue, Uncomplicated<\/li><li>Maxillary sinusitis, acute<\/li><li>Mycobacterium avium complex infection, Lung disease<\/li><li>Streptococcal pharyngitis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Anthrax<\/li><li>Bacterial endocarditis; Prophylaxis<\/li><li>Bacterial lower respiratory infection<\/li><li>Bartonellosis - HIV infection<\/li><li>Legionella pneumonia<\/li><li>Lyme disease<\/li><li>Mycobacteriosis<\/li><li>Pertussis<\/li><li>Spotted fevers<\/li><li>Ureaplasma urealyticum infection<\/li><\/ul>"}]},"3":{"id":"126900-s-3","title":"Contraindications\/Warnings","sub":[{"id":"126900-s-3-9","title":"Contraindications","mono":"<ul><li>cholestatic jaundice and\/or hepatic dysfunction associated with prior clarithromycin use<\/li><li>concomitant use with cisapride, pimozide, astemizole, terfenadine, ergotamine, or dihydroergotamine<\/li><li>concomitant use with colchicine in patients with renal or hepatic impairment<\/li><li>concomitant use with HMG-CoA reductase inhibitors extensively metabolized by CYP3A4 (eg, lovastatin or simvastatin)<\/li><li>hypersensitivity to clarithromycin or any component of the product, erythromycin, or any macrolide antibiotics<\/li><li>QT prolongation or ventricular cardiac arrhythmias, including torsade de pointes, history of<\/li><\/ul>"},{"id":"126900-s-3-10","title":"Precautions","mono":"<ul><li>acute hypersensitivity reactions, severe (eg, anaphylaxis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), Henoch-Schoenlein purpura) may occur; discontinue use immediately if suspected<\/li><li>Clostridium difficile associated diarrhea, ranging in severity from mild diarrhea to fatal colitis, has been reported; drug discontinuation may be necessary<\/li><li>concomitant use with phosphodiesterase inhibitors (ie, sildenafil, tadalafil, vardenafil) is not recommended<\/li><li>concomitant use with ranitidine bismuth citrate in patients with history of acute porphyria or creatinine clearance less than 25 mL\/min is not recommended<\/li><li>hepatotoxicity (eg, increased liver enzymes, and hepatocellular and\/or cholestatic hepatitis, with or without jaundice), severe and sometimes fatal, has been reported; discontinue use if suspected<\/li><li>myasthenia gravis, exacerbation or new onset, has been reported<\/li><li>pregnancy; fetal harm may occur; avoid use unless no appropriate alternative therapy<\/li><li>QT prolongation, arrhythmia, and cases of torsades de pointes, including fatalities, have been reported; increased risk in elderly patients; avoid use in patients with ongoing proarrhythmic conditions (eg, uncorrected hypokalemia or hypomagnesemia, or clinically significant bradycardia) and with concomitant use of Class IA (eg, quinidine, procainamide) or Class III (eg, dofetilide, amiodarone, sotalol) antiarrhythmics<\/li><li>renal impairment, severe, with or without hepatic impairment; dose adjustment may be necessary<\/li><\/ul>"},{"id":"126900-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"126900-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"126900-s-4","title":"Drug Interactions","sub":[{"id":"126900-s-4-13","title":"Contraindicated","mono":"<ul><li>Alfuzosin (theoretical)<\/li><li>Amifampridine (theoretical)<\/li><li>Astemizole (probable)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Colchicine (established)<\/li><li>Conivaptan (theoretical)<\/li><li>Dihydroergotamine (probable)<\/li><li>Dronedarone (theoretical)<\/li><li>Eletriptan (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Eplerenone (theoretical)<\/li><li>Ergoloid Mesylates (probable)<\/li><li>Ergonovine (probable)<\/li><li>Ergotamine (probable)<\/li><li>Fluconazole (probable)<\/li><li>Isavuconazonium Sulfate (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Lovastatin (theoretical)<\/li><li>Lurasidone (probable)<\/li><li>Maraviroc (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Methylergonovine (probable)<\/li><li>Methysergide (probable)<\/li><li>Naloxegol (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nimodipine (theoretical)<\/li><li>Pimozide (probable)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Saquinavir (established)<\/li><li>Silodosin (probable)<\/li><li>Simvastatin (probable)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"126900-s-4-14","title":"Major","mono":"<ul><li>Ado-Trastuzumab Emtansine (theoretical)<\/li><li>Afatinib (theoretical)<\/li><li>Ajmaline (theoretical)<\/li><li>Alprazolam (established)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amlodipine (established)<\/li><li>Amobarbital (theoretical)<\/li><li>Amprenavir (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aprepitant (probable)<\/li><li>Aprindine (theoretical)<\/li><li>Aprobarbital (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Atazanavir (established)<\/li><li>Atorvastatin (probable)<\/li><li>Avanafil (theoretical)<\/li><li>Axitinib (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Brentuximab Vedotin (theoretical)<\/li><li>Bretylium (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Butabarbital (theoretical)<\/li><li>Butalbital (theoretical)<\/li><li>Cabazitaxel (established)<\/li><li>Cabozantinib (theoretical)<\/li><li>Carbamazepine (established)<\/li><li>Ceritinib (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clonazepam (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabigatran Etexilate (established)<\/li><li>Dabrafenib (theoretical)<\/li><li>Daclatasvir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Dexamethasone (theoretical)<\/li><li>Digoxin (established)<\/li><li>Diltiazem (established)<\/li><li>Disopyramide (probable)<\/li><li>Docetaxel (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Dutasteride (theoretical)<\/li><li>Ebastine (theoretical)<\/li><li>Efavirenz (established)<\/li><li>Enzalutamide (theoretical)<\/li><li>Eribulin (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Estazolam (established)<\/li><li>Eszopiclone (theoretical)<\/li><li>Etravirine (probable)<\/li><li>Everolimus (theoretical)<\/li><li>Famotidine (theoretical)<\/li><li>Felbamate (theoretical)<\/li><li>Felodipine (established)<\/li><li>Fentanyl (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Fluticasone (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Galantamine (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (probable)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Halothane (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Hydroquinidine (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibrutinib (theoretical)<\/li><li>Ibutilide (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Ifosfamide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Irinotecan (theoretical)<\/li><li>Isoflurane (theoretical)<\/li><li>Isradipine (theoretical)<\/li><li>Itraconazole (probable)<\/li><li>Ivacaftor (theoretical)<\/li><li>Ixabepilone (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Letrozole (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lorcainide (theoretical)<\/li><li>Losartan (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Macitentan (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Mephobarbital (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Methohexital (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Midazolam (established)<\/li><li>Mifepristone (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Mizolastine (theoretical)<\/li><li>Modafinil (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nafcillin (theoretical)<\/li><li>Nicardipine (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nintedanib (theoretical)<\/li><li>Nisoldipine (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Olaparib (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Ospemifene (theoretical)<\/li><li>Oxcarbazepine (theoretical)<\/li><li>Oxycodone (established)<\/li><li>Palbociclib (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Paroxetine (probable)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Pentobarbital (theoretical)<\/li><li>Perampanel (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Perphenazine (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pipamperone (theoretical)<\/li><li>Pirmenol (theoretical)<\/li><li>Pixantrone (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Ponatinib (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Regorafenib (theoretical)<\/li><li>Retapamulin (theoretical)<\/li><li>Rifabutin (established)<\/li><li>Rifapentine (probable)<\/li><li>Rilpivirine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Ritonavir (established)<\/li><li>Roflumilast (theoretical)<\/li><li>Romidepsin (theoretical)<\/li><li>Ruxolitinib (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Secobarbital (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Sildenafil (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Sirolimus (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Spiramycin (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Sulfamethoxazole (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Suvorexant (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Tadalafil (theoretical)<\/li><li>Tamoxifen (theoretical)<\/li><li>Tamsulosin (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Temsirolimus (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Thiopental (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolterodine (probable)<\/li><li>Topotecan (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Tramadol (theoretical)<\/li><li>Trazodone (established)<\/li><li>Triazolam (established)<\/li><li>Trimethoprim (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Venlafaxine (theoretical)<\/li><li>Verapamil (established)<\/li><li>Vilanterol (theoretical)<\/li><li>Vilazodone (theoretical)<\/li><li>Vinblastine (probable)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Vinorelbine (established)<\/li><li>Vorapaxar (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Vorinostat (theoretical)<\/li><li>Warfarin (probable)<\/li><li>Zaleplon (theoretical)<\/li><li>Zidovudine (probable)<\/li><li>Zileuton (theoretical)<\/li><li>Zolpidem (theoretical)<\/li><\/ul>"},{"id":"126900-s-4-15","title":"Moderate","mono":"<ul><li>Acenocoumarol (probable)<\/li><li>Alfentanil (probable)<\/li><li>Bromocriptine (probable)<\/li><li>Conjugated Estrogens (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Darunavir (established)<\/li><li>Delavirdine (probable)<\/li><li>Diazepam (probable)<\/li><li>Esterified Estrogens (probable)<\/li><li>Estradiol (probable)<\/li><li>Estriol (probable)<\/li><li>Estrone (probable)<\/li><li>Estropipate (probable)<\/li><li>Ethinyl Estradiol (probable)<\/li><li>Glipizide (probable)<\/li><li>Glyburide (established)<\/li><li>Hexobarbital (probable)<\/li><li>Indinavir (probable)<\/li><li>Linezolid (probable)<\/li><li>Methylprednisolone (probable)<\/li><li>Nevirapine (established)<\/li><li>Pravastatin (probable)<\/li><li>Prednisone (probable)<\/li><li>Repaglinide (probable)<\/li><li>Rifampin (established)<\/li><li>Rivaroxaban (established)<\/li><li>Tipranavir (established)<\/li><\/ul>"}]},"5":{"id":"126900-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain (1% to 7.5%), Diarrhea (1.6% to 15%), Disorder of taste (0.4% to 18.9%), Indigestion (up to 3.8%), Nausea (3% to 28.3%), Vomiting (1% to 24.5%)<\/li><li><b>Neurologic:<\/b>Headache (up to 9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Prolonged QT interval (less than 1%)<\/li><li><b>Dermatologic:<\/b>Henoch-Schoenlein purpura, Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Gastrointestinal:<\/b>Clostridium difficile diarrhea<\/li><li><b>Hepatic:<\/b>Hepatitis (greater than or equal to 1%), Liver failure<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Drug hypersensitivity syndrome<\/li><\/ul>"},"6":{"id":"126900-s-6","title":"Drug Name Info","sub":{"0":{"id":"126900-s-6-17","title":"US Trade Names","mono":"<ul><li>Biaxin<\/li><li>Biaxin Filmtab<\/li><li>Biaxin XL<\/li><\/ul>"},"2":{"id":"126900-s-6-19","title":"Class","mono":"<ul><li>Antibiotic<\/li><li>Macrolide<\/li><\/ul>"},"3":{"id":"126900-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"126900-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"126900-s-7","title":"Mechanism Of Action","mono":"Systemic: Clarithromycin binds to the 50S ribosomal subunit of the 70S ribosome of susceptible organisms, thereby inhibiting bacterial RNA-dependent protein synthesis .<br\/>"},"8":{"id":"126900-s-8","title":"Pharmacokinetics","sub":[{"id":"126900-s-8-23","title":"Absorption","mono":"Systemic: Well absorbed; Bioavailability: 55%; food delays absorption <br\/>"},{"id":"126900-s-8-24","title":"Distribution","mono":"Systemic: Vd: 243 to 266 L <br\/>"},{"id":"126900-s-8-25","title":"Metabolism","mono":"Systemic: Hepatic: Active metabolite: 14-hydroxyclarithromycin <br\/>"},{"id":"126900-s-8-26","title":"Excretion","mono":"<ul><li>Systemic: Clarithromycin-; Fecal: 4%; Renal: 20 to 40%<\/li><li>14-Hydroxyclarithromycin- Renal: 10 to 15%<\/li><li>inhibitor of CYP3A and P-glycoprotein<\/li><li>substrate of CYP3A<\/li><\/ul>"},{"id":"126900-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Systemic:     :<\/li><li>Clarithromycin-Normal renal function- 250 mg every 12 hours-3 to 4 hours; 500 mg every 12 hours-5 to 7 hours.<\/li><li>14-Hydroxyclarithromycin-250 mg every 12 hours-5 to 6 hours; 500 mg every 12 hours-Approximately 7 hours.:<\/li><li>Renal function impairment (creatinine clearance of &lt; 30 mL per minute [0.5 mL per second])-Clarithromycin: Approximately 22 hours .<\/li><li>14-Hydroxyclarithromycin: Approximately 47 hours .<\/li><li>Systemic: Clarithromycin: 5 to 7 h<\/li><li>14-Hydroxyclarithromycin: 7 h<\/li><\/ul>"}]},"9":{"id":"126900-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>(immediate release tablets and suspension) may be taken with or without food<\/li><li>(extended-release tablets) take with food<\/li><li>(extended-release tablets) swallow whole; do not chew, break, or crush<\/li><li>(suspension) shake well before each use; do not refrigerate<\/li><\/ul>"},"10":{"id":"126900-s-10","title":"Monitoring","mono":"<ul><li>fever<\/li><li>CBC<\/li><li>symptomatic improvement<\/li><li>hepatic function<\/li><li>renal function<\/li><\/ul>"},"11":{"id":"126900-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Oral Powder for Suspension: 125 MG\/5 ML, 250 MG\/5 ML<\/li><li>Oral Tablet: 250 MG, 500 MG<\/li><li>Oral Tablet, Extended Release: 500 MG<\/li><\/ul><\/li><li><b>Biaxin Filmtab<\/b><br\/>Oral Tablet: 250 MG, 500 MG<br\/><\/li><li><b>Biaxin<\/b><br\/><ul><li>Oral Powder for Suspension: 250 MG\/5 ML<\/li><li>Oral Tablet: 250 MG, 500 MG<\/li><\/ul><\/li><li><b>Biaxin XL<\/b><br\/>Oral Tablet, Extended Release: 500 MG<br\/><\/li><\/ul>"},"12":{"id":"126900-s-12","title":"Toxicology","sub":[{"id":"126900-s-12-31","title":"Clinical Effects","mono":"<b>MACROLIDE ANTIBIOTICS <\/b><br\/>OVERDOSE: Significant toxicity following acute overdose is uncommon.  N\/V, abdominal pain may occur.  ADVERSE EFFECTS: N\/V, abdominal pain, diarrhea most common.  Cholestasis, sensorineural hearing loss, thrombophlebitis (IV administration), ventricular dysrhythmias\/QT prolongation (IV administration) are less common. <br\/>"},{"id":"126900-s-12-32","title":"Treatment","mono":"<b>MACROLIDE ANTIBIOTICS <\/b><br\/><ul><li>Decontamination: Activated charcoal, gastric lavage.<\/li><li>Support: Therapy as indicated.<\/li><li>Abdominal discomfort: Food, milk or an antacid  may be given; most effects reverse with drug cessation<\/li><li>Monitoring of patient: Baseline ECG, cardiac monitoring as indicated. Renal and hepatic function as indicated.<\/li><\/ul>"},{"id":"126900-s-12-33","title":"Range of Toxicity","mono":"<b>MACROLIDE ANTIBIOTICS<\/b><br\/>In general, the macrolide antibiotics are of a low order toxicity. <br\/>"}]},"13":{"id":"126900-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to immediately report signs\/symptoms of hepatotoxicity or Clostridium difficile-associated diarrhea (severe, watery, or bloody diarrhea).<\/li><li>This drug may cause abdominal pain, taste disorder, dyspepsia, nausea, diarrhea, or headache.<\/li><li>Patient should take extended-release tablets with food.<\/li><li>Advise patient there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><\/ul>"}}}